MIRA Pharmaceuticals, Inc. (MIRA) Research

MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.

Market snapshot

Symbol
MIRA
Price
$0.95
Day change
-2.64%
Market cap
$40.0M
P/E ratio
-4.07x
52-week range
0.9-2.45
Sector
Healthcare
Industry
Drug Manufacturers - General
Next earnings
in 2 months

Peer companies

  • AN2 Therapeutics, Inc. (ANTX)
  • Apimeds Pharmaceuticals US, Inc (APUS)
  • IGC Pharma, Inc. (IGC)
  • Milestone Scientific Inc. (MLSS)
  • Modular Medical, Inc. (MODD)
  • Myomo, Inc. (MYO)
  • NanoViricides, Inc. (NNVC)
  • Precision Optics Corporation, Inc. (POCI)

Recent insider activity

  • Whalen Matthew Pratt — A-Award (50000 shares) on 2026-06-12
  • Del Giudice Matthew Paul — A-Award (50000 shares) on 2026-06-12
  • MacPherson Edward Clouston — A-Award (50000 shares) on 2026-06-12
  • Shekhat Denil Nanji — A-Award (50000 shares) on 2026-06-12
  • Mushak Andriy — trade (0 shares) on 2026-06-02

Open MIRA Pharmaceuticals, Inc. (MIRA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.